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(p0.0003). Burden was recorded among caregivers of patients with (at inclusion)
euthymia (43.8  13.1; n329), mania (47.7  13.6; n41), hypomania (51.6  12.7;
n44), depression (49.9  14.4; n137), or mixed disease status (50.2  9.5; n20).
CONCLUSIONS: This ongoing study provides multinational perspectives on the
high burden experienced by caregivers of individuals with BD-I and BD-II in every-
day clinical practice settings. Study funded byAstraZeneca; Clinical Trials Registry:
NCT01062607.
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FOR DEMENTIA CARE IN THE UNITED STATES, 1998–2007
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OBJECTIVES: As data is limited, to determine national estimates and characteris-
tics of Alzheimer’s disease and senile dementia (ADSD) visits in the United States
(US) ambulatory setting. METHODS: Through a retrospective analysis of the 10-
year (1998-2007) physician-office visit data of National Ambulatory Medical Care
Survey, we calculated weighted national estimates and percentages of ADSD
visits made by patients aged 40 years and older with relevant ICD-9CM codes
(290.xx, 294.xx, 331.xx). In multivariate logistic regression we analyzed the charac-
teristics associated with anti-dementia drug mention at ADSD visits. RESULTS:
Of an estimated 6.5million adult ambulatory care visits (5 visits per 1000 people) for
ADSD, 52%, 25%, 20%, 14%, and 11%, mentioned an antidementia (memantine,
cholinesterase inhibitor, or donepezil/rivastigmine/gallantamine), anticholinergic,
antidepressant, antipsychotic, and antianxiety drug respectively. Patients with
ADSD visits were predominantly 75-84 year olds (53%), white (89%), female (63%),
living in metropolitan statistical area (81%), South (30%) and Northeast (28%), on
Medicare (73%), seeing a freestanding private practice physician (61%) or a neurol-
ogist (32%), established patient (88%), and reported hypertension (12%). In multi-
variate analyses controlling for gender, type of dementia, comorbidity, and visit-
year, any versus no anti-dementia drug mention was significantly less likely at
visits by other versus white-race patients (adjusted odds ratio [OR] is 0.44,95%CI:
0.42-0.46), new versus established patients (OR0.38;95%CI:0.37–0.39), by those on
self-pay versus private-insurance (OR0.63;95%CI:0.56–0.70), and in South
(OR0.43;95%CI:0.41–0.44) and West (OR0.41;95%CI:0.40–0.43) versus those in
Northeast (all P 0.0001). CONCLUSIONS: About 50% and 25% of ADSD visits
mentioned an anti-dementia drug and other drugs, respectively. New patients,
those of other races, on self-pay and living in South or West of the US were less
likely to receive an anti-dementia drug. Study findings’ suggest deficiencies in
access and quality of dementia care in the USwarranting the attention of providers
and payers and need further study.
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INTRODUCTION Although benzodiazepines are primarily considered anxiolytics,
some have other indications such as seizures, insomnia, alcohol withdrawal, and
tardive dyskinesia. They are also commonly abused medications, especially the
brandnameproducts, alone and in combinationwith other drugs (e.g.methadone).
They are classified, on the basis of their half lives, into short-, intermediate- and
long-acting agents. The side effects of falling and fractures cause benzodiazepines
to be unattractive for elderly patients. OBJECTIVES: To describe trends in the uti-
lization of, spending on, and average per-prescription spending on benzodiaz-
epines, individually, stratified by half life, and overall, for the U.S. Medicaid pro-
grams over the past two decades.METHODS: A retrospective, descriptive analysis
was performed using the national Medicaid pharmacy claims database, which has
information on outpatient prescription claims. Quarterly prescription counts and
reimbursement amountswere calculated for each of the benzodiazepines (branded
or generic) reimbursed by Medicaid. Average per-prescription spending was found
by dividing reimbursement by the number of prescriptions. RESULTS: Prescrip-
tions for benzodiazepines among Medicaid beneficiaries increased from 6.15 mil-
lion in 1991 to 16.70 million in 2009. Expenditures rose from $108.75 million to
$165.79 million over the same time period, implying an average per-prescription
price of approximately $10 in 2009. Whereas utilization of long-acting agents re-
mained relatively constant at 1.79 million prescriptions per year, prescriptions for
short-acting and intermediate-acting drugs rose from 1.74 million to 4.94 million,
and from 2.82 million to 9.91 million, respectively. Prescriptions for flurazepam
have fallen steadily from 439,106 in 1991 to 45,754 in 2009. CONCLUSIONS: Spend-
ing on benzodiazepines represents  1% of Medicaid’s spending on outpatient
drugs. Moreover, due to generic entry for some of the drugs, the percentage rise in
spending on benzodiazepines since 1991 (52.5%) was less than the general rate of
inflation (57.5%). By its policy of reimbursing for generic, rather than branded,
prescriptions, Medicaid reduces the opportunity for abuse.
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RISK-BENEFIT ANALYSIS OF DEPRESSION TREATMENT FOR CHILDREN AND
YOUNG ADULTS
Soeteman DI, Miller M, Kim J
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OBJECTIVES: The U.S. Food and Drug Administration’s decision to mandate a black-
boxwarning on antidepressants indicating that they are associatedwith an increased
risk of suicidal behavior in children and young adults remains controversial. We
aimed to quantify the tradeoffs of alternative strategies in treating pediatric major
depressive disorder (MDD) with respect to clinical benefit and risk of fatal and non-
fatal suicidal behavior over a five-year time horizon. METHODS: We developed a
disease simulationmodel integrating epidemiological and clinical data from the pub-
lished literature in order to simulate the effect of three treatment strategies (i.e., Se-
lective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a
combination of SSRIs andCBT) on aU.S. population of children and young adultswith
MDD. We explored the implications of different scenarios of data extrapolation be-
yond the time horizon of existing data and of uncertain assumptions about suicide
attempt risks and patients’ response to treatment. Main outcome measures were
symptom-free weeks, suicide attempts, and suicide deaths. RESULTS: In a cohort of
1,000,000 simulated children and young adults, there were more than twice as many
suicide deaths among those started on SSRIs (1291), compared to those started onCBT
(506) or combination treatment (621) over the first 36 weeks of treatment. Over a
five-year time horizon, this hierarchy of suicide risk persisted, even under assump-
tions most favorable to SSRIs. With respect to symptom-free weeks, combination
treatmentwas superior to both SSRIs and CBT alone, but this differencewasmarginal
over a five-year time horizon. CONCLUSIONS: Considering the risk-benefit profile
over a five-year period, CBT appears to offer a safer profile with respect to suicide
deaths and attempts than combination treatment or SSRIs alone. While combination
treatment maximizes symptom-free weeks, the additional benefit over the five-year
time horizon is modest and must be weighed against the clinically meaningful in-
crease in fatal suicides.
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COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST
FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS
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OBJECTIVES: Physicians often make dosage decisions based on experience and
heuristic factors in addition to the product label. This makes it difficult for econo-
mists to compare the “real world” costs and benefits of alternative therapeutic
choices. We compare a published methodology for calculating therapeutic dose
equivalence based on approved labeling for varous antipsychotics prescribed for
schizophrenia with actual prescription data in that population. METHODS: The
sample consisted of a proportional selection of patients that derived from a popu-
lation of patients of all ages, across all payers, and in all regions of the United
States. The information included NDC code sets, quantity, and day of supply and
was aggregated from pharmaceutical prescriptions files. The frequency distribu-
tion measured the top antipsychotic medications in patients diagnosed with
schizophrenia. The therapeutic dose equivalence was determined using themeth-
odology of Woods (2003) as the comparator. RESULTS: A total of 324,724 patients
with a diagnosis of schizophrenia were included in the study. Doses equivalent to
1mg/day of Risperidonewere 86.17mg/day of Quetiapine, 5.09mg/day of Olanzap-
ine, 5.25 mg/day of Aripiprazole, 92.28 mg/day of Clozapine, and 33.74 mg/day of
Ziprasidone. CONCLUSIONS:With the ever-increasing array of differntially-dosed
medications available, it is imperative for physicians and outcomes researchers to
utilize estimation of therapeutic dose equivalence that reflects actual practice pat-
terns so that informed decisions can be made evaluating the cost and cost-effec-
tiveness of various therapeutic choice. Our study enables pharmacoeconomic
comparisons among antispychotics not only according to label-approved dosages,
but also real-world dosing patterns.
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EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP’S) ON OPIOID
OVERDOSE ADMISSION
Painter JT
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Over the past three decades the concept of prescription monitoring
programs (PMPs) has developed immensely, however little evidence regarding
their effectiveness has been collected. This study focuses on simple difference-in-
difference evaluations, comparing the implementation effect of a PMP in Tennes-
see with Kentucky, which has a well-established PMP, andMissouri, which has not
to-date enacted legislation to develop a PMP. The effect of interest is opioid over-
dose hospital admission.METHODS: The present study examines a simple differ-
ence-in-difference model of a natural experiment caused by the staggered imple-
mentation of prescription monitoring programs in Kentucky, Missouri, and
Tennessee. We implement a pre-post design with the primary outcome of interest
being hospital admission due to opioid overdose. For this evaluation we use all
claims from Kentucky, Missouri, and Tennessee in the HCUP-NIS data from 2006
and 2008. The data is separated according to whether the hospital admission was
due to opioid overdose. Four models are examined: main effects, individual fixed
effects, and the full model, which takes into account both year and state fixed
effects and shows the true effect of the Tennessee implementation. Although the
findings in the Tennesseemodels trend positively, there are no significant findings
in the full model. RESULTS:We look at various models, including fixed effects for
state and year, but no consistently significant effect is seen. Despite no statistically
significant findings, coefficients do trend in expected directions suggesting a sound
model. CONCLUSIONS: There are multiple possible reasons for the lack of signifi-
cant findings, including several study limitations. Despite the limitations, it can be
said that the Controlled Substance Abuse Database Program in Tennessee has no
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